Related Experiment Video
Updated: May 2, 2026
10:12
Flash NanoPrecipitation for the Encapsulation of Hydrophobic and Hydrophilic Compounds in Polymeric Nanoparticles
Published on: January 7, 2019
24.5K
Summary
The U.S. Food and Drug Administration (FDA) has released draft guidance on nanotechnology. This analysis examines these documents, which are likely to become industry standards for FDA-regulated products.
Area of Science:
- Nanotechnology and its application in FDA-regulated products.
- Regulatory science and policy development.
Background:
- Nanotechnology presents transformative potential for FDA-regulated products.
- Existing FDA regulations for products with nanoscale materials are under scrutiny.
- The FDA has historically regulated products containing nanoscale materials.
Purpose of the Study:
- To analyze three (3) draft guidance documents recently issued by the FDA concerning nanotechnology.
- To provide commentary on these draft guidances for professionals in the field.
- To assess the implications of these guidances as potential de facto standards.
Main Methods:
- Review and examination of FDA draft guidance documents.
- Analysis of regulatory approaches to nanotechnology.
- Commentary on the practical application of the guidance.
Main Results:
- The FDA has issued three (3) draft guidance documents on nanotechnology within the last eighteen (18) months.
- These documents address the use of nanoscale materials in specific FDA-regulated products.
- The guidances are anticipated to establish de facto regulatory standards.
Conclusions:
- The draft guidance documents represent a significant step in the FDA's regulatory approach to nanotechnology.
- Practitioners in the field should carefully review and understand these documents.
- Further analysis and adaptation to these emerging standards will be necessary.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
01:25Drug Regulation
3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.9K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.9K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369